Aquinox Pharmaceuticals (NASDAQ:AQXP)

CAPS Rating: 1 out of 5

AQXP News and Commentary

Caps

How do you think AQXP will perform against the market?

Add Stock to CAPS Watchlist

All Players

26 Outperform
15 Underperform
 

All-Star Players

4 Outperform
13 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top AQXP Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TSIF (99.97)
Submitted August 07, 2015

I rarely, if ever, (maybe once in a blue moon...which actually was a few days ago)...pile in in the middle of a one day spike an equity, but this one clearly had mojo...the problem with jumping in on a runner, even if you hit it mid cycle is you have… More

zzlangerhans (99.80)
Submitted January 09, 2017

In July 2015 Aquinox was toast,. Subsequent to the failure of their sole clinical candidate in AQX-1125 in phase II trials for COPD and interstitial cystitis, the market cap was well under cash and the stock seemed to be on the way to the pennies as… More

AQXP VS S&P 500 (SPY)

AQXP Summary

Recent Community Commentary

Read the most recent pitches from players about AQXP.

Recs

0
Member Avatar TerryHogan (99.98) Submitted: 8/12/2017 1:07:37 AM : Underperform Start Price: $13.20 AQXP Score: -3.83

Big cash burn with no meaningful news until Q3 2018. Even then, it's not clear that the market for the drug is big enough to justify market cap.

Recs

1
Member Avatar zzlangerhans (99.80) Submitted: 1/9/2017 11:23:27 AM : Underperform Start Price: $16.12 AQXP Score: +25.92

In July 2015 Aquinox was toast,. Subsequent to the failure of their sole clinical candidate in AQX-1125 in phase II trials for COPD and interstitial cystitis, the market cap was well under cash and the stock seemed to be on the way to the pennies as the company burned its remaining runway on executive compensation. Then things got crazy. The company touted success in secondary endpoints of the interstitial cystitis trial, which the market largely yawned at. Then the biotech whale of whales Baker Brothers revealed a large position, which sent the share price from 2 to 30. Baker Brothers continued to increase their position as recently as this past November, which brought their total holdings to 10,536,092 shares. Topline data from the LEADERSHIP 301 phase III trial of AQX-1125 for interstitial cystitis are expected in Q4 2017, and it seemed like Baker Brothers was all in on a positive result. It worked with Pharmacyclics and Seattle Genetics (maybe not so much with Xoma, but wins are always remembered more than losses).

Everything was going great and the stock has been raging since the Trump Bump, but then there was a surprising SEC filing after hours last Friday. Aquinox will be assisting in the sale of, wait for it, 10,536,092 shares from current holders. Remember who owns exactly 10,536,092 shares? How could Baker Brothers suddenly dump out now, after so many smaller funds and retail traders put their faith in their serene wisdom (or even better their unfettered access to the executive suite)? The only logical conclusion is that Baker Brothers decided that raking in the huge profits contributed by their followers was a better financial strategy than potentially getting Xoma'd by phase III data.

As of this writing, Aquinox stock is only down 10% from Friday's high and trades at the same level it did at the beginning of last week. So the stock goes up 1500% when the Baker Brothers get in, and down 10% when they get out? Makes sense. Perhaps the Baker Brothers followers forgot they were followers and think Aquinox's 200M enterprise value is for LEADERSHIP and interstitial cystitis. I'd be surprised if more of them don't come to their senses over the next few days and weeks and scamper away from this sinking ship. I shorted another 500 shares at 15.95 this morning for total 1000 zzporte shares short cost basis 16.38.

Recs

0
Member Avatar jkgtrader (49.34) Submitted: 8/7/2015 4:05:05 PM : Underperform Start Price: $17.79 AQXP Score: +44.61

This stock rose very high but is likely to crash very soon.

Leaderboard

Find the members with the highest scoring picks in AQXP.

Score Leader

oscillation

oscillation (78.88) Score: +1,849.27

The Score Leader is the player with the highest score across all their picks in AQXP.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
mswanhart77 57.60 8/3/2015 Outperform 5Y $1.79 +739.11% +28.31% +710.79 0 Comment
guillu 60.15 8/3/2015 Outperform NS $1.79 +739.11% +28.31% +710.79 0 Comment
laikeatwoon < 20 8/7/2015 Outperform 5Y $3.36 +347.02% +29.91% +317.11 0 Comment
biocqr 26.94 8/25/2014 Outperform 5Y $6.45 +132.87% +34.93% +97.94 0 Comment
ccastineyra 87.92 8/27/2014 Outperform 5Y $6.61 +127.23% +34.74% +92.50 0 Comment
SFTuffy 83.98 10/2/2014 Outperform 5Y $6.70 +124.18% +39.07% +85.11 0 Comment
luh < 20 8/11/2015 Underperform 3M $28.00 -46.36% +29.23% +75.59 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. gftb5 < 20 9/18/2014 Outperform 5Y $7.30 +105.75% +33.87% +71.88 0 Comment
ronkzor < 20 4/16/2015 Outperform 5Y $8.04 +86.89% +28.55% +58.34 0 Comment
EvanBuck 99.93 8/17/2015 Underperform 5Y $21.29 -29.43% +28.65% +58.08 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackCanaccord < 20 10/16/2014 Outperform NS $6.21 +141.73% +47.52% +94.21 0 Comment

Featured Broker Partners